* The issuer did not co-operate; based on best available information.
Rating Rationale
Acuite has reaffirmed the long term rating of ‘ACUITE D’ (read as ACUITE D) on the Rs. 13.00 Crore bank facilities and ‘ACUITE C’ (read as ACUITE C) on the Rs. 4.54 Crore bank facilities of Phytochem Remedies India Private Limited (PRIPL). The rating is now indicative and is flagged as "Issuer not cooperating" on account of information risk and is based on the best available information.
About the Company
Udaipur, Rajasthan based, Phytochem Remedies India Private Limited was incorporated in 2002. It is engaged in the business of manufacturing of packing goods such as corrugated boxes, Cartons. The directors of the company are Mr. Niranjan Surana and Mrs. Aditi Bohra.
Unsupported Rating
Not Applicable
Non-cooperation by the issuer/borrower
Acuité has been requesting for data, information and undertakings from the rated entity for conducting surveillance & review of the rating. However, the issuer/borrower failed to submit such information before the due date. Acuité believes that information risk is a critical component in such ratings, and non-cooperation by the issuer along with unwillingness to provide information could be a sign of potential deterioration in its overall credit quality. This rating is, therefore, being flagged as “Issuer not-cooperating”, in line with prevailing SEBI regulations and Acuité’s policies.
Limitation regarding information availability
Rating Sensitivities
No information provided by the issuer / available for Acuité to comment upon.
Liquidity Position
No information provided by the issuer / available for Acuité to comment upon.
Outlook: Not Applicable
Other Factors affecting Rating
None
Particulars
Unit
FY 23 (Actual)
FY 22 (Actual)
Operating Income
Rs. Cr.
19.91
13.57
PAT
Rs. Cr.
0.84
0.53
PAT Margin
(%)
4.21
3.93
Total Debt/Tangible Net Worth
Times
3.15
1.86
PBDIT/Interest
Times
2.12
6.72
Status of non-cooperation with previous CRA
Not Applicable
Interaction with Audit Committee anytime in the last 12 months (applicable for rated-listed / proposed to be listed debt securities being reviewed by Acuite)